ArticleInternational journal of molecular sciences2022
Response of
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- The Mycobacterium abscessus cytochrome bcc:aaNature communications · 2026Article
- TheProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Growth-rate dependent response of mycobacteria to relief of inhibition by a bacteriostatic antibiotic.FEMS microbiology letters · 2026Article
- Mycobacterial respiratory chain enzymes and growth are inhibited by decylubiquinone.Communications biology · 2025Article
- Remission spectroscopy resolves the mechanism of action of bedaquiline within living mycobacteria.Nature communications · 2025Article
- Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria.International journal of molecular sciences · 2025Article
- Pyrroloquinolone-Based Compounds as a Novel Antimycobacterial Chemotype.ACS medicinal chemistry letters · 2025Article
- Article
- Inhibition mechanism of potential antituberculosis compound lansoprazole sulfide.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Article
- Nanosized Drug Delivery Systems to Fight Tuberculosis.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
For the design of next-generation tuberculosis chemotherapy, insight into bacterial defence against drugs is required. Currently, targeting respiration has attracted strong attention for combatting drug-resistant mycobacteria. Q203 (telacebec), an inhibitor of the cytochrome
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.